1-20 of 25
Keywords: Immunotherapy
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Further Areas
European Urology (1992) 21 (Suppl. 2): 2–6.
Published Online: 11 August 2017
... to the development of new, safer and more effective agents. Thus, BCG, an anachronism from the early days of tumour immunology, may lead cancer immunotherapy into the next century. 11 8 2017 Bacillus Calmette-Guérin Bladder cancer Immunotherapy 1992 Copyright / Drug Dosage / Disclaimer...
Journal Articles
Subject Area:
Further Areas
European Urology (1997) 31 (Suppl. 1): 5–9.
Published Online: 11 August 2017
... immunotherapy is very effective in vivo against the PAIII cell line, and it has significant growth inhibition against the Dunning MAT-LyLu cell line. Immunotherapy Prostate cancer Bropirimine 11 8 2017 1997 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...
Journal Articles
Subject Area:
Further Areas
European Urology (1997) 31 (Suppl. 1): 20–26.
Published Online: 11 August 2017
... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Immunotherapy Bropirimine Urinary tract Carcinoma in situ European Urology EurUrol 1997;31(suppl 1):20 26 1602931...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1995) 28 (4): 219–296.
Published Online: 11 August 2017
... from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Immunotherapy Interferon Clinical Paper Eur Urol 1995;28:291-296 1605300 Fernando Calais da Silva Linhares Furtado Mdrio Reis Fernando Carreira Vitor Dias Gomes Oliveira...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1993) 23 (3): 366–370.
Published Online: 11 August 2017
... Immunotherapy Medication, BCG Clinical Paper EurUrol 1993;23:366-370 1604943 JA. Witjesa A.P.M. v.d. Meijdena h W. Doesburgc F.M.J. Debruynea and the Members ofthe Dutch Southeast Cooperative Urological Group Departments of Urology, a University Hospital, Nijmegen, and b Bosch Medical Center, s...
Journal Articles
Subject Area:
Further Areas
European Urology (1977) 3 (1): 11–22.
Published Online: 11 August 2017
... to in the content or advertisements. Immunotherapy BCG Bladder tumor Eur. Urol. 3: 11-22 (1977) Nonspecific Immunotherapy with BCG Vaccine in Bladder Tumors A Preliminary Report 1603330 J.A. Martmez-Pineiro and P. Muntafiola Service of Urology, Department of Surgery, CS La Paz, Faculty of Medicine...
Journal Articles
Subject Area:
Further Areas
European Urology (1987) 13 (1-2): 103–109.
Published Online: 11 August 2017
..., instructions or products referred to in the content or advertisements. Renal cell carcinoma, advanced Immunotherapy Eur. Urol. 13: 103-109 (1987) © 1987 S. Karger AG, Basel 0302-2838/87/0132-0103S2.75/0 Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Renal Cell...
Journal Articles
Subject Area:
Further Areas
European Urology (1995) 27 (Suppl. 1): 2–8.
Published Online: 11 August 2017
.... In contrast, intravesical bacillus Calmette-Guérin (BCG) immunotherapy is effective in high-grade tumours,provides long-term protection from tumour recurrence and reduces disease progression. Controlled clinical trials have consistently demonstrated that BCG provides superior protection from tumour recurrence...
Journal Articles
Subject Area:
Further Areas
European Urology (1989) 16 (4): 271–277.
Published Online: 11 August 2017
... carcinoma Immunotherapy Interferon alpha-2a-vinblastine combination 11 8 2017 1989 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic...
Journal Articles
Subject Area:
Further Areas
European Urology (1990) 17 (2): 125–128.
Published Online: 11 August 2017
...A. Böhle; J. Schüller; A. Knipper; A. Hofstetter 14 patients with radiologically documented vesicorenal reflux (5 bilateral, 7 unilateral, 2 unilateral double-J stents) received intravesical immunotherapy with bacillus Calmette-Guérin (BCG) after treatment of their superficial urothelial tumors. 1...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 39 (5): 518–524.
Published Online: 14 May 2001
...Sven Brandau; Andreas Böhle Objectives: Using a human in vitro model we have previously identified so–called bacillus Calmette–Guérin (BCG)–activated killer (BAK) cells as potential effector cells in BCG immunotherapy. This study was designed to prove the hypothesis that BAK cells...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 38 (1): 115–118.
Published Online: 07 June 2000
...Paolo Lissoni; Mario Mandalà; Fernando Brivio IL–2 immunotherapy has been proven to be effective in the treatment of metastatic renal cell cancer (RCC). However, several drugs commonly used in the palliative therapy of cancer may potentially influence IL–2 efficacy, since the anticancer immunity...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 37 (Suppl. 3): 1–9.
Published Online: 05 May 2000
... is important for treatment outcome. Optimal results can be achieved by initiating treatment early (within 24 h after TUR) and for a duration of 6 months, and maintenance (>6 months) for patients with a delayed first instillation (>7 days after TUR). Bacillus Calmette-Guérin (BCG) immunotherapy has been...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 37 (Suppl. 3): 10–15.
Published Online: 05 May 2000
... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BCG Biological response modifiers Immunotherapy Bladder cancer Intravesical therapy has been successfully used for several decades in the management of superficial...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 37 (Suppl. 3): 34–40.
Published Online: 05 May 2000
... disease in this patient group compared to another not immunized with KLH. This prompted a variety of experimental and clinical studies using KLH as an immunotherapy for recurrent bladder cancer. Methods: Three different bladder cancer models have been used for experimental studies: intravesical...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 37 (4): 470–477.
Published Online: 17 March 2000
... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BCG Bladder neoplasm Maintenance therapy Immunotherapy Mycobacteria...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 37 (Suppl. 1): 1–8.
Published Online: 27 January 2000
...A. Böhle BCG immunotherapy against superficial bladder carcinoma recurrences is regarded as the most successful to date. However, the mode of action has not yet been fully explained. In this field, several European groups have recently significantly contributed by adding more details to the complex...